Kiniksa Pharmaceuticals International PLC (NAS:KNSA)
$ 22.52 0.91 (4.21%) Market Cap: 1.60 Bil Enterprise Value: 1.33 Bil PE Ratio: 204.82 PB Ratio: 3.69 GF Score: 62/100

Kiniksa Pharmaceuticals Ltd at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 11, 2021 / 09:30PM GMT
Release Date Price: $19.59 (+3.21%)
Anupam Rama
JPMorgan Chase & Co, Research Division - VP and Analyst

Welcome everyone to the 39th Annual JPMorgan Healthcare Conference. My name is Anupam Rama. I'm one of the senior biotech analysts here at JPMorgan. I'm joined by Matt Bannon and Tessa Romero from the team. Our next presenting company is Kiniksa.

And speaking on behalf of the company, we have CEO, Sanj Patel. Before I turn it over to Sanj, just wanted to highlight for those listeners on the webcast, you can submit a question via the ask the question button in the portal, and I'd be happy to ask the question on your behalf.

Sanj, I'll turn it over to you.

Sanj K. Patel
Kiniksa Pharmaceuticals, Ltd. - CEO & Chairman of the Board

Thanks, Anupam. I was just thinking that, and I can't believe it's been over 10 years together, you and I at this conference. It's actually -- time flies when you're having fun.

It's actually my 11th time presenting, but it's certainly the first in this format. But regardless, I do want to thank you and JPMorgan for hosting us today

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot